Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Retained Earnings (2016 - 2025)

Rocket Pharmaceuticals' Retained Earnings history spans 10 years, with the latest figure at -$31000.0 for Q4 2025.

  • For Q4 2025, Retained Earnings fell 146.97% year-over-year to -$31000.0; the TTM value through Dec 2025 reached -$31000.0, down 146.97%, while the annual FY2025 figure was -$31000.0, 146.97% down from the prior year.
  • Retained Earnings for Q4 2025 was -$31000.0 at Rocket Pharmaceuticals, down from -$9000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $319000.0 in Q4 2023 and bottomed at -$1.3 billion in Q2 2025.
  • The 5-year median for Retained Earnings is -$615000.0 (2023), against an average of -$331.1 million.
  • The largest annual shift saw Retained Earnings plummeted 1171119.05% in 2021 before it soared 189.36% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$491.9 million in 2021, then soared by 99.93% to -$357000.0 in 2022, then skyrocketed by 189.36% to $319000.0 in 2023, then crashed by 79.31% to $66000.0 in 2024, then crashed by 146.97% to -$31000.0 in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Retained Earnings are -$31000.0 (Q4 2025), -$9000.0 (Q3 2025), and -$1.3 billion (Q2 2025).